IL-9 protects against bleomycin-induced lung injury: Involvement of prostaglandins

American Journal of Pathology

Volumn 166, Issue 1, 2005, Pages 107-115

  Arras, Mohammed ^a   Louahed, Jamila ^a   Heilier, Jean François ^a   Delos, Monique ^b   Brombacher, Frank ^c   Renauld, Jean Christophe ^a   Lison, Dominique ^a   Huaux, François ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; INDOMETACIN; INTERLEUKIN 9; NEUTRALIZING ANTIBODY; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG INSTILLATION; EOSINOPHIL; GENE OVEREXPRESSION; HISTOLOGY; INTERMETHOD COMPARISON; LETHALITY; LUNG ALVEOLUS EPITHELIUM; LUNG INJURY; LUNG LAVAGE; MOLECULAR MECHANICS; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE; TRANSGENIC MOUSE; WILD TYPE;

EID: 11144229679     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)62236-5     Document Type: Article

References (60)

1. Adamson IY, Bowden DH: The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 1974, 77:185-197
2. Thrall RS, Barton RW: A comparison of lymphocyte populations in lung tissue and in bronchoalveolar lavage fluid of rats at various times during the development of bleomycin-induced pulmonary fibrosis. Am Rev Respir Dis 1984, 129:279-283
3. Nettelbladt O, Scheynius A, Bergh J, Tengblad A, Hallgren R: Alveolar accumulation of hyaluronan and alveolar cellular response in bleomycin-induced alveolitis. Eur Respir J 1991, 4:407-414
4. Smith RE, Strieter RM, Phan SH, Kunkel SL: C-C chemokines: novel mediators of the profibrotic inflammatory response to bleomycin challenge. Am J Respir Cell Mol Biol 1996, 15:693-702
5. Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P: Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med 1989, 170:655-663
6. Phan SH, Kunkel SL: Lung cytokine production in bleomycin-induced pulmonary fibrosis. Exp Lung Res 1992, 18:29-43
7. Hao H, Cohen DA, Jennings CD, Bryson JS, Kaplan AM: Bleomycin-induced pulmonary fibrosis is independent of eosinophils. J Leukoc Biol 2000, 68:515-521
8. Zhang K, Gharaee Kermani M, McGarry B, Remick D, Phan SH: TNF-alpha-mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis. J Immunol 1997, 158:954-959
9. Ma JY, Barger MW, Hubbs AF, Castranova V, Weber SL, Ma JK: Use of tetrandrine to differentiate between mechanisms involved in silica-versus bleomycin-induced fibrosis. J Toxicol Environ Health A 1999, 57:247-266
10. Chen ES, Greenlee BM, Wills-Karp M, Moller DR: Attenuation of lung inflammation and fibrosis in interferon-gamma-deficient mice after intratracheal bleomycin. Am J Respir Cell Mol Biol 2001, 24:545-555
11. Huaux F, Liu T, McGarry B, Ullenbruch M, Phan SH: Dual roles of IL-4 in lung injury and fibrosis. J Immunol 2003, 170:2083-2092
12. Arai T, Abe K, Matsuoka H, Yoshida M, Mori M, Goya S, Kida H, Nishino K, Osaki T, Tachibana I, Kaneda Y, Hayashi S: Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am J Physiol 2000, 278:L914-L922
13. Renauld J-C, van Snick J: Interleukin-9. The Cytokine Handbook. Edited by Thomson A, Lotze MT. London, Academic Press, 2003, pp 347-356
14. Renauld JC: New insights into the role of cytokines in asthma. J Clin Pathol 2001, 54:577-589
15. Arras M, Huaux F, Vink A, Delos M, Coutelier JP, Many MC, Barbarin V, Renauld JC, Lison D: Interleukin-9 reduces lung fibrosis and type 2 immune polarization induced by silica particles in a murine model. Am J Respir Cell Mol Biol 2001, 24:368-375
16. Grohmann U, van Snick J, Campanile F, Silla S, Giampietri A, Vacca C, Renauld JC, Fioretti MC, Puccetti P: IL-9 protects mice from gram-negative bacterial shock: suppression of TNF-alpha, IL-12, and IFN-gamma, and induction of IL-10. J Immunol 2000, 164:4197-4203
17. Renauld JC, van der Lugt N, Vink A, van Roon M, Godfraind C, Warnier G, Merz H, Feller A, Berns A, van Snick J: Thymic lymphomas in interleukin 9 transgenic mice. Oncogene 1994, 9:1327-1332
18. Kitamura D, Roes J, Kuhn R, Rajewsky K: A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 1991, 350:423-426
19. Kopf M, Brombacher F, Hodgkin PD, Ramsay AJ, Milbourne EA, Dai WJ, Ovington KS, Behm CA, Kohler G, Young IG, Matthaei KI: IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 1996, 4:15-24
20. van Snick J, Cayphas S, Vink A, Uyttenhove C, Coulie PG, Rubira MR, Simpson RJ: Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc Natl Acad Sci USA 1986, 83:9679-9683
21. Halatek T, Hermans C, Broeckaert F, Wattiez R, Wiedig M, Toubeau G, Falmagne P, Bernard A: Quantification of Clara cell protein in rat and mouse biological fluids using a sensitive immunoassay. Eur Respir J 1998, 11:726-733
22. Schneider T, Issekutz AC: Quantitation of eosinophil and neutrophil infiltration into rat lung by specific assays for eosinophil peroxidase and myeloperoxidase: application in a Brown Norway rat model of allergic pulmonary inflammation. J Immunol Methods 1996, 198:1-14
23. Yamamoto T, Takagawa S, Katayama I, Nishioka K: Anti-sclerotic effect of transforming growth factor-beta antibody in a mouse model of bleomycin-induced scleroderma. Clin Immunol 1999, 92:6-13
24. McCormick LL, Zhang Y, Tootell E, Gilliam AC: Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999, 163:5693-5699
25. Peebles RS, Jr., Dworski R, Collins RD, Jarzecka K, Mitchell DB, Graham BS, Shelter JR: Cyclooxygenase inhibition increases interleukin 5 and interleukin 13 production and airway hyperresponsiveness in allergic mice. Am J Respir Crit Care Med 2000, 162:676-681
26. Keerthisingam CB, Jenkins RG, Harrison NK, Hernandez-Rodriguez NA, Booth H, Laurent GJ, Hart SL, Foster ML, McAnulty RJ: Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 2001, 158:1411-1422
27. Peters-Golden M, Bailie M, Marshall T, Wilke C, Phan SH, Toews GB, Moore BB: Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med 2002, 165:229-235
28. Beller TC, Friend DS, Maekawa A, Lam BK, Austen KF, Kanaoka Y: Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis. Proc Natl Acad Sci USA 2004, 101:3047-3052
29. Onuma T, Holland JF, Masuda H, Waligunda JA, Goldberg GA: Microbiological assay of bleomycin: inactivation, tissue distribution, and clearance. Cancer 1974, 33:1230-1238
30. Li Q, Park PW, Wilson CL, Parks WC: Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 2002, 111:635-646
31. Li XP, Zhang HY, Soledad-Conrad V, Zhuang JJ, Uhal BD: Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo. Am J Physiol 2003, 284:L501-L507
32. Daly HE, Baecher-Allan CM, Barth RK, D'Angio CT, Finkelstein JN: Bleomycin induces strain-dependent alterations in the pattern of epithelial cell-specific marker expression in mouse lung. Toxicol Appl Pharmacol 1997, 142:303-310
33. Daly HE, Baecher-Allan CM, Paxhia AT, Ryan RM, Barth RK, Finkelstein JN: Cell-specific gene expression reveals changes in epithelial cell populations after bleomycin treatment. Lab Invest 1998, 78:393-400
34. Louahed J, Renauld JC, Demoulin JB, Baughman G, Bourgeois S, Sugamura K, van Snick J: Differential activity of dexamethasone on IL-2-, IL-4-, or IL-9- induced proliferation of murine factor-dependent T cell lines. J Immunol 1996, 156:3704-3710
35. Gazzinelli RT, Wysocka M, Hieny S, Scharton Kersten T, Cheever A, Kuhn R, Muller W, Trinchieri G, Sher A: In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN- gamma, and TNF-alpha. J Immunol 1996, 157:798-805
36. Zhao MQ, Stoler MH, Liu AN, Wei B, Soguero C, Hahn YS, Enelow RI: Alveolar epithelial cell chemokine expression triggered by antigen-specific cytolytic CD8(+) T cell recognition. J Clin Invest 2000, 106:R49-R58
37. Okamoto M, Kato S, Oizumi K, Kinoshita M, Inoue Y, Hoshino K, Akira S, McKenzie AN, Young HA, Hoshino T: Interleukin 18 (IL-18) in synergy with IL-2 induces lethal lung injury in mice: a potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia. Blood 2002, 99:1289-1298
38. Szapiel SV, Elson NA, Fulmer JD, Hunninghake GW, Crystal RG: Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis 1979, 120:893-899
39. Helene M, Lake Bullock V, Zhu J, Hao H, Cohen DA, Kaplan AM: T cell independence of bleomycin-induced pulmonary fibrosis. J Leukoc Biol 1999, 65:187-195
40. Schrier DJ, Phan SH, McGarry BM: The effects of the nude (nu/nu) mutation on bleomycin-induced pulmonary fibrosis: a biochemical evaluation. Am Rev Respir Dis 1983, 127:614-617
41. Sharma SK, MacLean JA, Pinto C, Kradin RL: The effect of an anti-CD3 monoclonal antibody on bleomycin-induced lymphokine production and lung injury. Am J Respir Crit Care Med 1996, 154:193-200
42. Li G, Siddiqui J, Hendry M, Akiyama J, Edmondson J, Brown C, Allen L, Levitt S, Poulain F, Hawgood S: Surfactant protein-A-deficient mice display an exaggerated early inflammatory response to a beta-resistant strain of influenza A virus. Am J Respir Cell Mol Biol 2002, 26:277-282
43. Huaux F, Liu TJ, McGarry B, Ullenbruch M, Xing Z, Phan SH: Eosinophils and T lymphocytes possess distinct roles in bleomycin-induced lung injury and fibrosis. J Immunol 2003, 171:5470-5481
44. Dombrowicz D, Capron M: Eosinophils, allergy, and parasites. Curr Opin Immunol 2001, 13:716-720
45. Kobayashi T, Iijima K, Kita H: Marked airway eosinophilia prevents development of airway hyper-responsiveness during an allergic response in IL-5 transgenic mice. J Immunol 2003, 170:5756-5763
46. Vink A, Warnier G, Brombacher F, Renauld JC: Interleukin 9-induced in vivo expansion of the B-1 lymphocyte population. J Exp Med 1999, 189:1413-1423
47. Blobe GC, Schiemann WP, Lodish HF: Role of transforming growth factor beta in human disease. N Engl J Med 2000, 342:1350-1358
48. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, Annunziata N, Doestchman T: Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992, 359:693-699
49. Nakao A, Fujii M, Matsumura R, Kumano K, Saito Y, Miyazono K, Iwamoto I: Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 1999, 104:5-11
50. Tilley SL, Coffman TM, Koller BH: Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001, 108:15-23
51. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP: Prostaglandins as modulators of immunity. Trends Immunol 2002, 23:144-150
52. Reddy RC, Chen GH, Tateda K, Tsai WC, Phare SM, Mancuso P, Peters-Golden M, Standiford TJ: Selective inhibition of COX-2 improves early survival in murine endotoxemia but not in bacterial peritonitis. Am J Physiol 2001, 281:L537-L543
53. Myers LK, Kang AH, Postlethwaite AE, Rosloniec EF, Morham SG, Shlopov BV, Goorha S, Ballou LR: The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum 2000, 43:2687-2693
54. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM, Gorry SA, Trzaskos JM: Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995, 378:406-409
55. Moore BB, Coffey MJ, Christensen P, Sitterding S, Ngan R, Wilke CA, McDonald R, Phare SM, Peters-Golden M, Paine III R, Toews GB: GM-CSF regulates bleomycin-induced pulmonary fibrosis via a prostaglandin- dependent mechanism. J Immunol 2000, 165:4032-4039
56. Thrall RS, McCormick JR, Jack RM, McReynolds RA, Ward PA: Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin. Am J Pathol 1979, 95:117-130
57. Mall G, Zimmermann P, Siemens I, Burkhardt A, Otto HF: Prevention of bleomycin-induced fibrosing alveolitis with indomethacin: stereological studies on rat lungs. Virchows Arch A Pathol Anat Histopathol 1991, 419:339-347
58. Gavett SH, Madison SL, Chulada PC, Scarborough PE, Qu W, Boyle JE, Tiano HF, Lee CA, Langenbach R, Roggli VL, Zeldin DC: Allergic lung responses are increased in prostaglandin H synthase-deficient mice. J Clin Invest 1999, 104:721-732
59. Reilly TP, Brady JN, Marchick MR, Bourdi M, George JW, Radonovich MF, Pise-Masison CA, Pohl LR: A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. Chem Res Toxicol 2001, 14:1620-1628
60. Gao L, Zackert WE, Hasford JJ, Danekis ME, Milne GL, Remmert C, Reese J, Yin H, Tai HH, Dey SK, Porter NA, Morrow JD: Formation of prostaglandins E2 and D2 via the isoprostane pathway: a mechanism for the generation of bioactive prostoglandins independent of cyclooxygenase. J Biol Chem 2003, 278:28479-28489